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1. To assess the incidence of stress hyperglycemia in patients with AMI in non-diabetic patients. 
2. To compare the severity of coronary artery disease in patients, with stress hyperglycemia to 
























































Utility of HbA1c Levels for Diabetes Case Finding in Hospitalized Patients with Hyperglycemia
Patients presenting to the hospital with an acute illness and found to be hyperglycemic on admission 
can have either stress-related hyperglycemia or unrecognized impairment of glucose tolerance, 
including frank diabetes. A sizable proportion of this population will truly have diabetes; with 
prevalence estimates from 7 to 63%.There is at present no quick and accurate method for distinguishing 
between these two conditions (16). 
The oral glucose tolerance test (OGTT) is impractical because of dietary and cost constraints, it is less 
convenient and acceptable to patients, and it may even be contraindicated in acutely ill patients. The 
fasting plasma glucose (PG) test, on the hand, would require the coordination of at least two morning 
fasting levels. HbA1c level is considered an important monitoring tool in treating patients with diabetes, 
but it is not currently recommended for screening or for the diagnosis of diabetes.  HbA1c level reflects 
the average plasma glucose to which the hemoglobin is exposed during the erythrocyte’s life span of 
90 days and may be less influenced by the acute stress of illness(16). 
Although the utility of HbA1c levels for diagnosis and screening of diabetes has been studied in the 
general population, its role in differentiating patients with true diabetes from those with random stress-
induced hyperglycemia in the hospital has not been previously investigated (16). 
The use of the HbA1c level can play a major role in diabetes case finding in hospitalized patients with 
random hyperglycemia, where the operating characteristics of the test approach those of the traditional 
fasting plasma glucose for the diagnosis of diabetes. An admission HbA1c level is a quick and 
convenient tool for the diagnosis of diabetes and, in 50% of the cases, could eliminate the need for 
further diagnostic testing (through fasting plasma glucose or oral glucose tolerance test 
determinations). This quicker diagnosis of diabetes with the HbA1c level can also translate into an early 
inpatient mobilization of diabetes support services (e.g., nutrition and education), treatment, and even 




































One proposed link between hyperglycemia and poor cardiovascular outcomes is the effect of acute 
hyperglycemia on the vascular endothelium. In addition to serving as a barrier between blood and 
tissues, vascular endothelial cells play a critical role in overall homeostasis. In the healthy state, the 
vascular endothelium maintains the vasculature in a quiescent, relaxant, antithrombotic, antioxidant, 
and antiadhesive state. During illness the vascular endothelium is subject to dysregulation, dysfunction, 
insufficiency, and failure (18)
Endothelial cell dysfunction is linked to increased cellular adhesion, perturbed angiogenesis, increased 
cell permeability, inflammation, and thrombosis. Commonly, endothelial function is evaluated by 
measuring endothelial-dependent vasodilatation, looking most often at the brachial artery. Human in 
vivo studies utilizing this parameter confirm that acute hyperglycemia to the levels commonly seen in 
the hospital setting (142–300 mg/dl or 7.9–16.7 mmol/l) causes endothelial dysfunction (18)
 Hyperglycemia may directly alter endothelial cell function by promoting chemical inactivation of 
nitric oxide Other mechanisms include triggering production of reactive oxygen species (ROS) or 
activating other pathways (rev. Despite compelling experimental data, studies examining a possible 
association among hyperglycemia, endothelial function, and outcomes have not to date been done in 

















Multiple studies have identified a variety of hyperglycemia-related abnormalities in hemostasis, 
favoring thrombosis. For example, hyperglycemic changes in rats rapidly reduce plasma fibrinolytic 
activity and tissue plasminogen activator activity while increasing plasminogen activator inhibitor 
(PAI)-1 activity (18). 
Human studies in patients with type 2 diabetes have shown platelet hyperactivity indicated by increased 
thromboxane biosynthesis. Thromboxane biosynthesis decreases with reduction in blood glucose. 
Hyperglycemia-induced elevations of interleukin (IL)-6 levels have been linked to elevated plasma 
fibrinogen concentrations and fibrinogen mRNA. Increased platelet activation as shown by shear-
induced platelet adhesion and aggregation on extracellular matrix has been demonstrated in patients 
with diabetes (18). 
As little as 4 hours of acute hyperglycemia enhances platelet activation in patients with type 2 diabetes. 
In a crossover, double-blind study, 12 patients were subjected to hyperglycemic (250 mg/dl, 13.9 
mmol/l) and euglycemic (100 mg/dl, 5.55 mmol/l) clamps. Hyperglycemia precipitated stress-induced 
platelet activation as well as platelet P-selectin and lysosomal integral membrane protein (LIMP) 
expression. Hyperglycemia also caused increased plasma von Willebrand factor antigen, von 
Willebrand factor activity and urinary 11-dehydro-thromboxane B2 (a measure of thromboxane A2 
production). These changes were not seen in the euglycemic state. If hyperglycemia-induced platelet 
hyperreactivity is particularly evident with high–shear stress conditions, as suggested in the above 
studies, this finding may explain the increased thrombotic events commonly seen in hospitalized 




















































Hyperglycemia and immune function
The association of hyperglycemia and infection has long been recognized, although the overall 
magnitude of the problem is still somewhat unclear. From a mechanistic point of view, the primary 
problem has been identified as phagocyte dysfunction. Studies have reported diverse defects in 
neutrophil and monocyte function, including adherence, chemotaxis, phagocytosis, bacterial killing, and 
respiratory burst (18). 
Bagdade et al. were among the first to attach a glucose value to improvement in granulocyte function 
when they demonstrated significant improvement in granulocyte adherence as the mean fasting blood 
glucose was reduced from 293 ± 20 to 198 ± 29 mg/dl (16.3–11 mmol/l) in 10 poorly controlled 
patients with diabetes. Other investigators have demonstrated similar improvements in leukocyte 
function with treatment of hyperglycemia. In vitro trials attempting to define hyperglycemic thresholds 
found only rough estimates that a mean glucose >200 mg/dl (11.1 mmol/l) causes leukocyte dysfunction 
(22) 
Alexiewicz et al. demonstrated elevated basal levels of cytosolic calcium in the polymorphonuclear 
leukocytes (PMNs) of patients with type 2 diabetes relative to control subjects. Elevated cytosolic 
calcium was associated with reduced ATP content and impaired phagocytosis. There was a direct 
correlation between PMN cytosolic calcium and fasting serum glucose. These were both inversely 
proportional to phagocytic activity. Glucose reduction with glyburide resulted in reduced cytosolic 
calcium, increased ATP content, and improved phagocytosis. Classic microvascular complications of 
diabetes are caused by alterations in the aldose reductase pathway, advanced glycated end products 
(AGE) pathway, reactive oxygen species pathway, and the protein kinase C (PKC) pathway. Several of 
these pathways may contribute to immune dysfunction. PKC may mediate the effect of hyperglycemia 
on neutrophil dysfunction (23).
 Liu et al. found that decreased phagocytic activity in diabetic mice correlated inversely with the 
formation of advanced glycation end products, although a direct cause-and-effect relationship was not 
proven (24). 
Ortmeyer and Mohsenin found that hyperglycemia caused impaired superoxide formation along with 
suppressed activation of phospholipase D. Reduced superoxide formation has been linked to leukocyte 
dysfunction. Another recent study found a link among hyperglycemia, inhibition of glucose-6-
phosphate dehydrogenase, and reduced superoxide production in isolated human neutrophils (25)  
Sato and colleagues used chemiluminescence’s to evaluate neutrophil bactericidal function. The 
authors confirmed a relationship between hyperglycemia and reduced superoxide formation in 
neutrophils. This defect was improved after treatment with an aldose reductase inhibitor. This finding 
suggests that increased activity of the aldose reductase pathway makes a significant contribution to the 
incidence of diabetes-related bacterial infections. Laboratory evidence of the effect of hyperglycemia 
on the immune system goes beyond the granulocyte. Nonenzymatic glycation of immunoglobulin has 
been reported. Normal individuals exposed to transient glucose elevation show rapid reduction in 
lymphocytes, including all lymphocyte subsets (28). 
In patients with diabetes, hyperglycemia is similarly associated with reduced T-cell populations for both 
CD-4 and CD-8 subsets. These abnormalities are reversed when glucose is lowered. In summary, 
studies evaluating the effect of hyperglycemia on the immune system comprise small groups of normal 
individuals, patients with diabetes of various duration and types, and animal studies. These studies 
consistently show that hyperglycemia causes immunosuppression. Reduction of glucose by a variety of 































































            Potential relationships between metabolic stress hyperglycemia, 
            hypoinsulinemia, and poor hospital outcomes
To explain the dual role of glucose and insulin on hospital outcomes, Levetan and Magee proposed the 
following relationships. Elevations in counter regularory hormones accelerate catabolism, hepatic 
gluconeogenesis, and lipolysis. These events elevate blood glucose, free fatty acids, ketones, and 
lactate. The rise in glucose blunts insulin secretion via the mechanism of glucose toxicity, resulting in 
further hyperglycemia (27). 
The vicious cycle of stress-induced hyperglycemia and hypoinsulinemia subsequently causes 
maladaptive responses in immune function, fuel production, and synthesis of mediators that cause 
further tissue and organ dysfunction. Thus, the combination of hyperglycemia and relative 
hypoinsulinemia is mechanistically positioned to provide a plausible explanation for the poor hospital 
outcomes seen in observational studies (27).   
                 
























































































Stress hyperglycemia and Cardiac surgery.
Attainment of targeted glucose control in the setting of cardiac surgery is associated with reduced 
mortality and risk of deep sternal wound infections. Furnary and colleagues (46, 47) treated cardiac 
surgery patients with diabetes with either subcutaneous insulin (years 1987–1991) or with intravenous 
insulin (years 1992–2003) in the perioperative period. From 1991–1998, the target glucose range was 
150 -200 mg/dl (8.3–11.1 mmol/l); in 1999 it was dropped to 125–175 mg/dl (6.9–9.7 mmol/l), and in 
2001 it was again lowered to 100–150 mg/dl (5.5–8.3 mmol/l). 
Following implementation of the protocol in 1991, the authors reported a decrease in blood glucose 
level for the first 2 days after surgery and a concomitant decrease in the proportion of patients with 
deep wound infections, from 2.4% (24 of 990) to 1.5% (5 of 595) (P < 0.02) (47). A recent analysis or 
the cohort found a positive correlation between the average postoperative glucose level and mortality, 
with the lowest mortality in patients with average postoperative blood glucose <150 mg/dl (8.3 mmol/l) 
(48). 
Golden et al. (49) performed a nonconcurrent prospective cohort chart review study in cardiac surgery 
patients with diabetes (n = 411). Perioperative glucose control was assessed by the mean of six 
capillary blood glucose measures performed during the first 36 h following surgery. The overall 
infectious complication rate was 24.3%.
 After adjustment for variables, patients with higher mean capillary glucose readings were at increased 
risk of developing infections. Compared with subjects in the lowest quartile for blood glucose, those in 
quartiles 2–4 were at progressively increased risk for infection (RR 1.17, 1.86, and 1.78 for quartiles 2, 
3, and 4, respectively, P = 0.05 for trend). These data support the concept that perioperative 
hyperglycemia is an independent predictor of infection in patients with diabetes. 
Stress hyperglycemia and Critical care.
Van den Berghe et al. (50) performed a prospective, randomized controlled study of 1,548 adults who 
were admitted to a surgical intensive care unit and were receiving mechanical ventilation. Reasons for 
ICU admission were cardiac surgery ( 60%) and noncardiac indications, including neurologic disease 
(cerebral trauma or brain surgery), other thoracic surgery, abdominal surgery or peritonitis, vascular 
surgery, multiple trauma, or burns and transplant (4–9% each group). 
Patients were randomized to receive intensive insulin therapy (IIT) to maintain target blood glucose in 
the 80–110 mg/dl (4.4–6.1) range or conventional therapy to maintain target blood glucose between 
180 and 200 mg/dl (10–11.1 mmol/l). Insulin infusion was initiated in the conventional treatment group 
only if blood glucose exceeded 215 mg/dl (11.9 mmol/l), and the infusion was adjusted to maintain the 
blood glucose level between 180 and 200 mg/dl (10.0 and 11.1 mmol/l). After the patients left the ICU 
they received standard care in the hospital with target blood glucose of 180 and 200 mg/dl (10.0 and 
11.1 mmol/l). 
Ninety-nine percent of patients in the IIT group received insulin infusion, as compared with 39% of the 
patients in the conventional treatment group. In the IIT arm, blood glucose levels were 103 ± 19 mg/dl 
(5.7 ± 1.1 mmol/l) and in conventional treatment 153 ± 33 mg/dl (8.5 ± 1.8 mmol/l). IIT reduced 
mortality during ICU care from 8.0% with conventional treatment to 4.6% (P < 0.04). The benefit of 
IIT was attributable to its effect on mortality among patients who remained in the unit for more than 5 
days (20.2% with conventional treatment vs. 10.6% with IIT, P = 0.005). IIT also reduced overall 
inhospital mortality by 34%. In a subsequent analysis, Van den Berghe (55) demonstrated that for each 
20 mg/dl (1.1 mmol/l), glucose was elevated >100 mg/dl (5.5 mmol/l) and the risk of ICU death 
increased by 30% (P < 0.0001). 
Daily insulin dose (per 10 units added) was found as a positive rather than negative risk factor, 
suggesting that it was not the amount of insulin that produced the observed reduction in mortality. 
Hospital and ICU survival were linearly associated with ICU glucose levels, with the highest survival 
rates occurring in patients achieving an average blood glucose <110 mg/dl (6.1 mmol). An 
improvement in outcomes was found in patients who had prior diabetes as well as in those who had no 
history of diabetes. 
Evidence for a blood glucose threshold in cardiac surgery and critical care.
Furnary et al. (46) and Zerr et al. (49) identified a reduction in mortality throughout the blood glucose 
spectrum with the lowest mortality in patients with blood glucose <150 mg/dl (8.3 mmol/l). 
Van den Berghe et al. (50), using intensive intravenous insulin therapy, reported a 45% reduction in 
ICU mortality with mean blood glucose of 103 mg/dl (5.7 mmol/l), as compared with the conventional 
treatment arm, where mean blood glucose was 153 mg/dl (8.5 mmol/l) in a mixed group of patients 































































































































Age >55 30 28 30 .004
Male sex 33 39 49 .329
Hypertensive 13 18 34 .089
smokers 18 12 14 .044
HDL <40 31 41 49 .577
LDL>130 30 27 38 .035


































































































































   Age >55 3.376 1.921 .869 13.109 .079
  Male sex 6.223 6.282 1.488 26.027 .012













AWMI .298 2.1 6.7E 1.3 .110
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GLOSSARY FOR THE MASTER SHEET 
DM    -        Diabetes mellitus.
AMI       -        Acute myocardial infarction.
SH    - Stress hyperglycemia
CAD    - Coronary artery disease
CAG     - Coronary angiogram
NGT    - Normal Glucose tolerance
TG    -       Triglycerides
HDL       -      High density cholesterol
LDL    - Low density cholesterol
HbA1c   - Glycosylated haemoglobin A1c
OGTT     ­       Oral glucose tolerance test
PG           ­       Plasma glucose
STEMI    ­       ST elevation myocardial infarction
PAI          ­      Plasminogen activator inhibitor 1 activity
IL             ­      Interleukin
PCI          ­      Percutaneous coronary intervention
IIT            ­      Intensive insulin therapy
CHF          ­     Congestive heart failure.
ACS        ­       Acute coronary syndrome
